ArticleDiscover oncology2025
The hidden pathway: biological aging as a mediator between diabetes and breast cancer risk: a Mendelian randomized study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus and cancer: A systematic review and meta-analysis of Mendelian randomization studies.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the relationship between type 2 diabetes mellitus and the risk of developing breast cancer and its subtypes, and the mediating role of biological aging in it.
methodsA two-sample Mendelian randomized analyses were performed to assess the effect of type 2 diabetes mellitus on breast cancer and its subtypes, and the mediating effect of biological aging between type 2 diabetes mellitus with breast cancer and its subtypes was explored by mediation analysis. All the data were based on genome-wide association studies. The data of type 2 diabetes mellitus were obtained from meta-analyses with the UK Biobank and FinnGen. The data of biological aging and breast cancer were obtained from UK Biobank, Breast Cancer Association Consortium, respectively.
resultsThe results of univariate Mendelian randomized showed that type 2 diabetes mellitus was positively causally associated with the risk of triple-negative breast cancer (OR = 1.076, 95%CI 1.022 ~ 1.132, P = 0.005), and positively associated with the biological aging phenotype PhenoAgeAccel (OR = 1.311, 95%CI 1.221 ~ 1.407, P < 0.001) and BioAgeAccel (OR = 1.083, 95%CI 1.054 ~ 1.113, P < 0.001) were both positively causal. The results of mediation analysis showed that BioAgeAccel played a fully mediating role in the causal effect of type 2 diabetes mellitus and triple-negative breast cancer, with a mediating effect of -0.010 (95%CI -0.020 ~ -0.001).
conclusionThrough Mendelian randomized analyses, this study explores the potential causal link between type 2 diabetes mellitus and the risk of triple-negative breast cancer, as well as the possible mediating role of biological ageing. The findings indicate a potential association between type 2 diabetes mellitus and an increased risk of triple-negative breast cancer, with BioAgeAccel possibly acting as a mediator. However, given the limitations of the study and the current evidence, it is premature to definitively establish a causal relationship and the precise mediating effect. Further research is necessary to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.